Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma Esterases | Zendy

Niklas Lindegårdh | Zendy; Geraint Davies | Zendy; Tran Tinh Hien | Zendy; Jeremy Farrar | Zendy; Pratap Singhasiva | Zendy; Nicholas Day | Zendy; Nicholas J. White | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma Esterases

Author(s) -

Niklas Lindegårdh,

Geraint Davies,

Tran Tinh Hien,

Jeremy Farrar,

Pratap Singhasiva,

Nicholas Day,

Nicholas J. White

Publication year - 2006

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00500-06

Subject(s) - prodrug , active metabolite , esterase , dichlorvos , metabolite , ex vivo , chemistry , drug , oseltamivir , pharmacology , in vivo , pharmacokinetics , phosphate , chromatography , biochemistry , enzyme , biology , in vitro , medicine , microbiology and biotechnology , disease , covid-19 , pesticide , infectious disease (medical specialty) , agronomy

The anti-influenza drug oseltamivir is an ester prodrug activated by hepatic carboxylesterases. Plasma esterases also convert up to 31.8% of the parent compound to the active metabolite after 4 h ex vivo, with wide interindividual variation. This source of error is removed by adding the esterase inhibitor dichlorvos to blood collection tubes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research